<ul><li>Tvaster Genkalp, a molecular diagnostics firm, has secured $1.25 million in a pre-series A funding round led by Ideaspring Capital.</li><li>The funding will be used to accelerate the expansion and commercialization of Episcreen Liver, a methylation-based liquid biopsy test for early liver cancer detection.</li><li>Tvaster aims to provide a non-invasive and highly accurate diagnostic alternative for Hepatocellular Carcinoma (HCC), the most common form of liver cancer.</li><li>The company is also working on developing a test for Cholangiocarcinoma and a chemotherapy resistance test for pediatric hepatoblastoma.</li></ul>

Tvaster Genkalp secures $1.25 million from Ideaspring Capital

Discover more